- Home
- AHG vs VSTM Comparison
AHG vs VSTM Comparison
Compare AHG & VSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AHG | VSTM |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 757.9M | 723.8M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | AHG | VSTM |
|---|---|---|
| Price | $1.60 | $6.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $13.38 |
| AVG Volume (30 Days) | 33.2K | ★ 1.9M |
| Earning Date | 08-14-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,777,798.00 | $13,379,000.00 |
| Revenue This Year | N/A | $208.54 |
| Revenue Next Year | N/A | $251.40 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 512.09 | 33.79 |
| 52 Week Low | $0.83 | $4.01 |
| 52 Week High | $2.10 | $11.25 |
Technical Indicators
Market Signals| Indicator | AHG | VSTM |
|---|---|---|
| Relative Strength Index (RSI) | 56.00 | 36.48 |
| Support Level | $1.31 | $6.31 |
| Resistance Level | $1.62 | $6.78 |
| Average True Range (ATR) | 0.14 | 0.61 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 79.41 | 8.17 |
Price Performance
Historical ComparisonAbout AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.